Reverb Therapeutics, a biotech company leveraging the natural immune system to treat life-threatening diseases, has raised $17 million in financing.
The funding round was led by founding investor Amplitude Ventures and included participation from the Myeloma Investment Fund, KdT Ventures, Finchley Healthcare Ventures, Seido Capital, and InBC Investment Corp.
Reverb’s Amplify•R™ platform utilizes bispecific antibody engineering and data-driven modeling to modulate cytokine activity while avoiding common challenges like systemic toxicity and manufacturing issues. The company’s initial focus is on cancer and autoimmune diseases.
Preclinical studies have demonstrated proof-of-concept for Reverb’s approach, showing the ability to redirect endogenous cytokines and shrink tumors. The company’s lead program, AMP01, targets PD-1 while delivering IL-15, a key protein that enhances T-cell activity.
“With this funding, we will take our lead IL-15 bispecific program to the candidate stage and develop additional programs spanning other cytokines and cellular targets,” said Reverb CEO David de Graaf, Ph.D.
Amplitude Ventures’ Bharat Srinivasa, Ph.D., noted the potential of the Amplify•R platform, stating that its approach overcomes hurdles that have hindered previous cytokine-based therapies.
Leave a Reply